Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?
Identifieur interne : 000D54 ( Main/Corpus ); précédent : 000D53; suivant : 000D55Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?
Auteurs : Iago Dillion Lima Cavalcanti ; Sandrelli Meridiana De Fátima Ramos Dos Santos Medeiros ; Daniel Charles Dos Santos Macêdo ; Isabella Macário Ferro Cavalcanti ; Mariane Cajubá De Britto Lira NogueiraSource :
- Current drug delivery [ 1875-5704 ] ; 2020.
Abstract
In response to the global outbreak caused by SARS-CoV-2, this article aims to propose the development of nanosystems for the delivery of hydroxychloroquine in the respiratory system to the treatment of COVID-19. Performed a descriptive literature review, using the descriptors 'COVID-19', 'Nanotechnology', 'Respiratory Syndrome' and 'Hydroxychloroquine', in the PubMed, ScienceDirect and SciElo databases. After analyzing the articles according to the inclusion and exclusion criteria, they were divided into 3 sessions: Coronavirus: definitions, classifications and epidemiology, pharmacological aspects of hydroxychloroquine and pharmaceutical nanotechnology in targeting of drugs. We used 131 articles published until July 18, 2020. Hydroxychloroquine seems to promote a reduction in viral load, in vivo studies, preventing the entry of SARS-CoV-2 into lung cells, and the safety of its administration is questioned due to the toxic effects that it can develop, such as retinopathy, hypoglycemia and even cardiotoxicity. Nanosystems for the delivery of drugs in the respiratory system may be a viable alternative for the administration of hydroxychloroquine, which may enhance the therapeutic effect of the drug with a consequent decrease in its toxicity, providing greater safety for implementation in the clinic in the treatment of COVID-19.
DOI: 10.2174/1567201817666200827110445
PubMed: 32860358
Links to Exploration step
pubmed:32860358Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?</title><author><name sortKey="Cavalcanti, Iago Dillion Lima" sort="Cavalcanti, Iago Dillion Lima" uniqKey="Cavalcanti I" first="Iago Dillion Lima" last="Cavalcanti">Iago Dillion Lima Cavalcanti</name><affiliation><nlm:affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="De Fatima Ramos Dos Santos Medeiros, Sandrelli Meridiana" sort="De Fatima Ramos Dos Santos Medeiros, Sandrelli Meridiana" uniqKey="De Fatima Ramos Dos Santos Medeiros S" first="Sandrelli Meridiana" last="De Fátima Ramos Dos Santos Medeiros">Sandrelli Meridiana De Fátima Ramos Dos Santos Medeiros</name><affiliation><nlm:affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Dos Santos Macedo, Daniel Charles" sort="Dos Santos Macedo, Daniel Charles" uniqKey="Dos Santos Macedo D" first="Daniel Charles" last="Dos Santos Macêdo">Daniel Charles Dos Santos Macêdo</name><affiliation><nlm:affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Ferro Cavalcanti, Isabella Macario" sort="Ferro Cavalcanti, Isabella Macario" uniqKey="Ferro Cavalcanti I" first="Isabella Macário" last="Ferro Cavalcanti">Isabella Macário Ferro Cavalcanti</name><affiliation><nlm:affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="De Britto Lira Nogueira, Mariane Cajuba" sort="De Britto Lira Nogueira, Mariane Cajuba" uniqKey="De Britto Lira Nogueira M" first="Mariane Cajubá" last="De Britto Lira Nogueira">Mariane Cajubá De Britto Lira Nogueira</name><affiliation><nlm:affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32860358</idno><idno type="pmid">32860358</idno><idno type="doi">10.2174/1567201817666200827110445</idno><idno type="wicri:Area/Main/Corpus">000D54</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D54</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?</title><author><name sortKey="Cavalcanti, Iago Dillion Lima" sort="Cavalcanti, Iago Dillion Lima" uniqKey="Cavalcanti I" first="Iago Dillion Lima" last="Cavalcanti">Iago Dillion Lima Cavalcanti</name><affiliation><nlm:affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="De Fatima Ramos Dos Santos Medeiros, Sandrelli Meridiana" sort="De Fatima Ramos Dos Santos Medeiros, Sandrelli Meridiana" uniqKey="De Fatima Ramos Dos Santos Medeiros S" first="Sandrelli Meridiana" last="De Fátima Ramos Dos Santos Medeiros">Sandrelli Meridiana De Fátima Ramos Dos Santos Medeiros</name><affiliation><nlm:affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Dos Santos Macedo, Daniel Charles" sort="Dos Santos Macedo, Daniel Charles" uniqKey="Dos Santos Macedo D" first="Daniel Charles" last="Dos Santos Macêdo">Daniel Charles Dos Santos Macêdo</name><affiliation><nlm:affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Ferro Cavalcanti, Isabella Macario" sort="Ferro Cavalcanti, Isabella Macario" uniqKey="Ferro Cavalcanti I" first="Isabella Macário" last="Ferro Cavalcanti">Isabella Macário Ferro Cavalcanti</name><affiliation><nlm:affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="De Britto Lira Nogueira, Mariane Cajuba" sort="De Britto Lira Nogueira, Mariane Cajuba" uniqKey="De Britto Lira Nogueira M" first="Mariane Cajubá" last="De Britto Lira Nogueira">Mariane Cajubá De Britto Lira Nogueira</name><affiliation><nlm:affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Current drug delivery</title><idno type="eISSN">1875-5704</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In response to the global outbreak caused by SARS-CoV-2, this article aims to propose the development of nanosystems for the delivery of hydroxychloroquine in the respiratory system to the treatment of COVID-19. Performed a descriptive literature review, using the descriptors 'COVID-19', 'Nanotechnology', 'Respiratory Syndrome' and 'Hydroxychloroquine', in the PubMed, ScienceDirect and SciElo databases. After analyzing the articles according to the inclusion and exclusion criteria, they were divided into 3 sessions: Coronavirus: definitions, classifications and epidemiology, pharmacological aspects of hydroxychloroquine and pharmaceutical nanotechnology in targeting of drugs. We used 131 articles published until July 18, 2020. Hydroxychloroquine seems to promote a reduction in viral load, in vivo studies, preventing the entry of SARS-CoV-2 into lung cells, and the safety of its administration is questioned due to the toxic effects that it can develop, such as retinopathy, hypoglycemia and even cardiotoxicity. Nanosystems for the delivery of drugs in the respiratory system may be a viable alternative for the administration of hydroxychloroquine, which may enhance the therapeutic effect of the drug with a consequent decrease in its toxicity, providing greater safety for implementation in the clinic in the treatment of COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32860358</PMID><DateRevised><Year>2020</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-5704</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>Current drug delivery</Title><ISOAbbreviation>Curr Drug Deliv</ISOAbbreviation></Journal><ArticleTitle>Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/1567201817666200827110445</ELocationID><Abstract><AbstractText>In response to the global outbreak caused by SARS-CoV-2, this article aims to propose the development of nanosystems for the delivery of hydroxychloroquine in the respiratory system to the treatment of COVID-19. Performed a descriptive literature review, using the descriptors 'COVID-19', 'Nanotechnology', 'Respiratory Syndrome' and 'Hydroxychloroquine', in the PubMed, ScienceDirect and SciElo databases. After analyzing the articles according to the inclusion and exclusion criteria, they were divided into 3 sessions: Coronavirus: definitions, classifications and epidemiology, pharmacological aspects of hydroxychloroquine and pharmaceutical nanotechnology in targeting of drugs. We used 131 articles published until July 18, 2020. Hydroxychloroquine seems to promote a reduction in viral load, in vivo studies, preventing the entry of SARS-CoV-2 into lung cells, and the safety of its administration is questioned due to the toxic effects that it can develop, such as retinopathy, hypoglycemia and even cardiotoxicity. Nanosystems for the delivery of drugs in the respiratory system may be a viable alternative for the administration of hydroxychloroquine, which may enhance the therapeutic effect of the drug with a consequent decrease in its toxicity, providing greater safety for implementation in the clinic in the treatment of COVID-19.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cavalcanti</LastName><ForeName>Iago Dillion Lima</ForeName><Initials>IDL</Initials><AffiliationInfo><Affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Fátima Ramos Dos Santos Medeiros</LastName><ForeName>Sandrelli Meridiana</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos Macêdo</LastName><ForeName>Daniel Charles</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferro Cavalcanti</LastName><ForeName>Isabella Macário</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Britto Lira Nogueira</LastName><ForeName>Mariane Cajubá</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Laboratory of Immunopathology Keizo-Asami (LIKA), Federal University of Pernambuco (UFPE), Recife-PE. Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Drug Deliv</MedlineTA><NlmUniqueID>101208455</NlmUniqueID><ISSNLinking>1567-2018</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine.
</Keyword><Keyword MajorTopicYN="N">Nanotechnology</Keyword><Keyword MajorTopicYN="N">Respiratory Syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32860358</ArticleId><ArticleId IdType="pii">CDD-EPUB-109515</ArticleId><ArticleId IdType="doi">10.2174/1567201817666200827110445</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000D54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32860358
|texte= Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32860358" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |